Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection

A rapid and simple high-performance liquid chromatographic method for the determination of the R-(−)- and S-(+)-enantiomers of the antiepileptic drug vigabatrin in human plasma is described. After adding the internal standard (1-aminomethyl-cycloheptyl-acetic acid), plasma samples (200 μL) are depro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2007-07, Vol.854 (1), p.63-67
Hauptverfasser: Franco, Valentina, Mazzucchelli, Iolanda, Fattore, Cinzia, Marchiselli, Roberto, Gatti, Giuliana, Perucca, Emilio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A rapid and simple high-performance liquid chromatographic method for the determination of the R-(−)- and S-(+)-enantiomers of the antiepileptic drug vigabatrin in human plasma is described. After adding the internal standard (1-aminomethyl-cycloheptyl-acetic acid), plasma samples (200 μL) are deproteinized with acetonitrile and the supernatant is derivatized with 2,4,6 trinitrobenzene sulfonic acid (TNBSA). Separation is achieved on a reversed-phase cellulose-based chiral column (Chiralcel-ODR, 250 mm × 4.6 mm i.d.) using 0.05 M potassium hexafluorophosphate (pH 4.5)/acetonitrile/ethanol (50:40:10 vol/vol/vol) as mobile phase at a flow-rate of 0.9 mL/min. Chromatographic selectivity is improved by concentrating the derivatives on High Performance Extraction Disk Cartridges prior to injection. Detection is at 340 nm. Calibration curves are linear ( r 2 ≥ 0.999) over the range of 0.5–40 μg/mL for each enantiomer, with a limit of quantification of 0.5 μg/mL for both analytes. The assay is suitable for therapeutic drug monitoring and for single-dose pharmacokinetic studies in man.
ISSN:1570-0232
1873-376X
DOI:10.1016/j.jchromb.2007.03.042